



Press release

Cantargia AB
556791-6019
24 October 2016

Cantargia raises MSEK 24.6 through exercise of warrants

The exercise period for warrants of series TO 2 (not listed) and warrants of series TO 4 (listed) closed on October 18th 2016. In total 3.237.816 warrants of both series were exercised, resulting in a utilization of over 98 percent. Through the warrants, Cantargia raises around MSEK 24.6, before issue costs.

Warrants of series TO 2 were issued in connection with a debt-for-equity swap in October 2014 and warrants of series TO 4 were issued in connection with the initial public offering in March 2015. In total, 394.688 warrants of series TO 2 and 2.843.128 warrants of series TO 4 were exercised, resulting in the registration of 3.237.816 new shares at the Swedish Companies Registration Office. Cantargia will thereby get approximately MSEK 24.6 before issue costs. The number of shares will after registration at the Swedish Companies Registration Office amount to 20.917.200 shares and the share capital will be SEK 1.673.376.

"We are obviously very pleased with the strong support that our shareholders have shown us during this subscription period," says Göran Forsberg, CEO. "The interest shown regarding the intensified investment in our programs, is most stimulating."

If you have any questions concerning Cantargia's warrants, please contact:

Sedermera Fondkommission
Telephone: +46 (0)40-615 14 10
E-mail: info@sedermera.se

For further information, please contact

Göran Forsberg, CEO
Telephone: 046-275 62 60
E-mail: goran.forsberg@cantargia.com
Certified Adviser: Sedermera Fondkommission

This constitutes information that Cantargia is required to publish under the EU's Market Abuse Regulation. The information was submitted for publication through the above contact person on 24 October 2016, at 08.30.

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor associated protein "IL1RAP", in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.

Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company's Certified Adviser. More information about Cantargia is available at <http://www.cantargia.com>.